logo

For the Inventor, By the Inventor

Seattle, WA, United States of America

Oncogen


USPTO Granted Patents = 48


Forward Citations = 1,596

Loading Chart...
Loading Chart...

45 inventors (with patents filed for the assignee):

goldMedal Karl E Hellstrom (17 out of 32 patents)

silverMedal Ingegerd E Hellstrom (16 out of 32 patents)

bronzeMedal George J Todaro (13 out of 24 patents)

4.  Hans Marquardt (10 out of 20 patents)

5.  Mohammed Shoyab (9 out of 20 patents)

6.  Joseph P Brown (8 out of 19 patents)

7.  Daniel R Twardzik (7 out of 28 patents)

8.  Anthony F Purchio (7 out of 13 patents)

9.  Peter S Linsley (6 out of 77 patents)

10.  Diane Horn (5 out of 9 patents)

11.  Gregory D Plowman (3 out of 44 patents)

12.  Timothy M Rose (3 out of 11 patents)

13.  H Perry Fell (3 out of 8 patents)

14.  Shiu-Lok Hu (3 out of 3 patents)

15.  Mario N Lioubin (3 out of 3 patents)


Core Competencies:
Polypeptide Therapeutics
Tumor Immunotherapy
Chimeric Antibodies
Monoclonal Antibodies
Transforming Growth Factor-Beta
Therapeutic Antibody Fusion Proteins
HIV Inhibition
Melanoma Vaccines
Immunoconjugates
B-Cell Proliferation
Oncostatin M
Biologically Active Lipids

48 patents:

1. 6194200 - Expression systems for preparation of polypeptides in prokaryotic cells (2001-02-27),
2. 5786456 - Bp 50-specific antibodies and fragments thereof (1998-07-28),
3. 5766588 - Tumor immunotherapy using anti-idiotypic antibodies (1998-06-16),
4. 5645835 - Therapeutic antibody based fusion proteins (1997-07-08),
5. 5614610 - Tumor immunotherapy using anti-idiotypic antibodies (1997-03-25),
6. 5597578 - TGF-.beta. protein compositions for inhibition of cell proliferation (1997-01-28),
7. 5545548 - Thermally stable cytosine deaminase from saccharomyces (1996-08-13),
8. 5482856 - Production of chimeric antibodies by homologous recombination (1996-01-09),
9. 5340925 - Normal human growth regulatory receptor for TGF-.beta. (1994-08-23),
10. 5314995 - Therapeutic interleukin-2-antibody based fusion proteins (1994-05-24),
11. 5262177 - Recombinant viruses encoding the human melanoma-associated antigen (1993-11-16),
12. 5248666 - Methods for inhibiting neoplastic cell proliferation using platelet (1993-09-28),
13. 5247069 - Ligands and methods for augmenting B-cell proliferation (1993-09-21),
14. 5244793 - TGF-.beta.1/.beta.2: a novel chimeric transforming growth factor-beta (1993-09-14),
15. 5242824 - Monoclonal antibody to human carcinomas (1993-09-07),
Oncogen is a groundbreaking biotechnology company specializing in oncology research and drug discovery. With a mission to revolutionize cancer treatment, we leverage cutting-edge technologies to identify innovative therapeutic targets and develop personalized therapies. Our dedicated team of scientists, clinicians, and industry experts work collaboratively to advance the understanding and treatment of various types of cancer. Through strategic partnerships and rigorous research, we aim to improve patient outcomes and make a meaningful impact in the fight against cancer.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

48 Patents

#47 in Seattle, WA

#146 in Washington

#7,021 in US

#14,113 in the World

...
Seattle, WA, United States of America

Oncogen

Forward Citations = 1,596

45 inventors:

goldMedal Karl E Hellstrom (17 out of 32 patents)

silverMedal Ingegerd E Hellstrom (16 out of 32 patents)

bronzeMedal George J Todaro (13 out of 24 patents)

4.  Hans Marquardt (10 out of 20 patents)

5.  Mohammed Shoyab (9 out of 20 patents)

Please report any incorrect information to support@idiyas.com
Loading…